Sunday, May 20 , 2018, 5:41 am | Fair 56º

 
 
 
 

UCSB Professor Develops Drug Delivery Method That Could Slow Progression of Kidney Disease

Renal cyst fluid contains growth factors that cause the excessive proliferation and cyst growth associated with polycystic kidney disease.
Renal cyst fluid contains growth factors that cause the excessive proliferation and cyst growth associated with polycystic kidney disease. (Contributed photo)

For the 12 million people worldwide who suffer from polycystic kidney disease (PKD), an inherited disorder with no known cure, a new treatment option may be on the horizon.

Weimbs
Thomas Weimbs (Sonia Fernandez / UCSB photo)

PKD is a condition in which clusters of benign cysts develop within the kidneys. They vary in size, and as they accumulate more and more fluid, they can become very large. Among the common complications of PKD are high blood pressure and kidney failure.

Now, Thomas Weimbs, a professor in UC Santa Barbara’s Department of Molecular, Cellular, and Developmental Biology, has developed a novel strategy for targeting therapeutic antibodies to polycystic kidneys. He notes that the strategy opens up the possibility of repurposing a large number of existing drugs for PKD therapy.

Therapeutic antibodies — a class of biologics — are already being used extensively to treat a variety of diseases from cancer to autoimmune disorders. These biologic therapies use an antibody class called immunoglobulin-G (IgG) to bind to and prevent the activity of specific proteins or growth factors. However, in PKD, the growth factors shown to promote cyst growth reside in fluid trapped in the interior space of a cyst, called a lumen, to which IgG antibodies have no access.

Weimbs and his team have found a method that enables another class of antibodies, immunoglobulin-A (IgA), to penetrate the cyst wall. The researchers’ results appear in the Journal of Biological Chemistry.

Weimbs, who has been working on PKD for more than a decade, had an aha moment when he remembered his previous research as postdoctoral scholar at UC San Francisco. This research dealt with the question of how IgA could cross a cell layer by binding to polymeric immunoglobulin receptors (pIgR). Earlier work Weimbs conducted at UCSB had shown that the transcription factor called STAT6 is overly active in PKD, and he also recalled that STAT6 had been shown to drive the expression of pIgR in other organs.

“I put one and one together,” Weimbs said. “I thought if STAT6 is highly active in polycystic kidneys, maybe it also expresses a lot of pIgR — and that turned out to be the case. So we tested this in mouse models and in human polycystic kidney tissues, and, in both cases, high levels of pIgR were expressed in kidney cysts.”

Weimbs and his team found that when they injected IgA into mice, about 7 percent of the injected IgA remained inside the cyst lumens of polycystic kidneys.

“This suggests that the IgA gets taken up and is trapped inside because these cysts don’t have an exit,” Weimbs said. “So we end up with a way of exploiting the pIgR system for targeting these antibodies specifically to the polycystic kidney.”

The key is using molecular cloning to reformat an existing IgG antibody to IgA. Then the pIgR system carries the IgA antibody inside the cyst, where it neutralizes a specific receptor.

“Our strategy allows for the repurposing of thousands of existing monoclonal antibodies that have already been developed, which opens up a whole new class of therapeutics not previously used for PKD therapy,” Weimbs concluded. “This paper is proof of concept that we can use IgA to target polycystic kidneys. The next hurdle will be proof of therapeutic efficacy where we actually take an IgA antibody targeted to a specific protein or growth factor and see if it can inhibit cyst growth.”

— Julie Cohen represents the UCSB Office of Public Affairs and Communications.

Support Noozhawk Today

You are an important ally in our mission to deliver clear, objective, high-quality professional news reporting for Santa Barbara, Goleta and the rest of Santa Barbara County. Join the Hawks Club today to help keep Noozhawk soaring.

We offer four membership levels: $5 a month, $10 a month, $25 a month or $1 a week. Payments can be made through PayPal below, or click here for information on recurring credit-card payments.

Thank you for your vital support.

Become a Supporter

Enter your email
Select your membership level
×

Payment Information

You are purchasing:

Payment Method

Pay by Credit Card:

Mastercard, Visa, American Express, Discover

Pay with Apple Pay or Google Pay:

Noozhawk partners with Stripe to provide secure invoicing and payments processing.

  • Ask
  • Vote
  • Investigate
  • Answer

Noozhawk Asks: What’s Your Question?

Welcome to Noozhawk Asks, a new feature in which you ask the questions, you help decide what Noozhawk investigates, and you work with us to find the answers.

Here’s how it works: You share your questions with us in the nearby box. In some cases, we may work with you to find the answers. In others, we may ask you to vote on your top choices to help us narrow the scope. And we’ll be regularly asking you for your feedback on a specific issue or topic.

We also expect to work together with the reader who asked the winning questions to find the answer together. Noozhawk’s objective is to come at questions from a place of curiosity and openness, and we believe a transparent collaboration is the key to achieve it.

The results of our investigation will be published here in this Noozhawk Asks section. Once or twice a month, we plan to do a review of what was asked and answered.

Thanks for asking!

Click Here to Get Started >

Reader Comments

Noozhawk is no longer accepting reader comments on our articles. Click here for the announcement. Readers are instead invited to submit letters to the editor by emailing them to [email protected]. Please provide your full name and community, as well as contact information for verification purposes only.

Daily Noozhawk

Subscribe to Noozhawk's A.M. Report, our free e-Bulletin sent out every day at 4:15 a.m. with Noozhawk's top stories, hand-picked by the editors.

Sign Up Now >